Tue, May 20, 9:33 PM (29 days ago)
**Sigyn Therapeutics, Inc. (SIGY) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $0 (no revenue generated). - **Net Loss:** $668,564 (Q1 2025) vs. $758,088 (Q1 2024). - **Operating Expenses:** $546,059 (Q1 2025) vs. $629,972 (Q1 2024). - **Cash Flow:** Net cash used in operating activities was $294,446 (Q1 2025) vs. $235,612 (Q1 2024). - **Cash Position:** $12,895 (Q1 2025) vs. $12,144 (Q4 2024). **Profit Margins & Cash Flow:** - **Operating Margin:** Negative, with significant operating losses. - **Cash Flow from Financing:** $295,197 (Q1 2025) from short-term convertible notes. **Earnings Changes & Quarterly Performance:** - **Earnings per Share (EPS):** $(0.42) (Q1 2025) vs. $(0.62) (Q1 2024). - **Share Price Impact:** No significant impact due to lack of revenue and ongoing losses. **Trends & Uncertainties:** - **Going Concern:** Significant doubt about the company's ability to continue as a going concern due to accumulated deficit of $15,350,288 and working capital deficit of $5,083,920. - **Funding:** Plans to raise additional funds through public offerings or asset sales. - **Operational History:** Limited historical financial information and no revenue since inception. **Future Operations Impact:** - **Strategic Value:** Potential strategic value to pharmaceutical, dialysis, and organ transplant industries if therapies are successfully advanced. - **Market Opportunities:** Addressing unmet needs in global health, including infectious diseases and cancer therapies. - **Regulatory Pathway:** Class III medical devices requiring Pre-Market Approval (PMA) from the FDA. **Key Metrics:** - **Total Assets:** $244,309 (Q1 2025) vs. $213,719 (Q4 2024). - **Total Liabilities:** $5,189,516 (Q1 2025) vs. $4,671,343 (Q4 2024). - **Stockholders' Deficit:** $(4,945,207) (Q1 2025) vs. $(4,457,624) (Q4 2024). **Conclusion:** Sigyn Therapeutics faces significant financial challenges, including substantial losses, limited cash reserves, and a going concern. The company is focused on developing therapeutic solutions for unmet medical needs but requires additional funding to sustain operations and advance its pipeline. The regulatory pathway for its products is complex, involving extensive clinical trials and FDA approval processes.